JPS61176532A - プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法 - Google Patents

プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法

Info

Publication number
JPS61176532A
JPS61176532A JP60017077A JP1707785A JPS61176532A JP S61176532 A JPS61176532 A JP S61176532A JP 60017077 A JP60017077 A JP 60017077A JP 1707785 A JP1707785 A JP 1707785A JP S61176532 A JPS61176532 A JP S61176532A
Authority
JP
Japan
Prior art keywords
precursor
plasminogen activator
salt
activator precursor
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60017077A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0479326B2 (enExample
Inventor
Kazuo Morimoto
森本　和郎
Motofumi Sagane
嵯峨根　素史
Kazuhiro Ohara
大原　和宏
Shusaku Narita
成田　修策
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Green Cross Corp Korea filed Critical Green Cross Corp
Priority to JP60017077A priority Critical patent/JPS61176532A/ja
Priority to KR1019860000415A priority patent/KR940000540B1/ko
Priority to ES551324A priority patent/ES8802582A1/es
Priority to CA000500493A priority patent/CA1283047C/en
Priority to EP86300596A priority patent/EP0190041A3/en
Publication of JPS61176532A publication Critical patent/JPS61176532A/ja
Priority to US07/512,511 priority patent/US5075230A/en
Publication of JPH0479326B2 publication Critical patent/JPH0479326B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP60017077A 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法 Granted JPS61176532A (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP60017077A JPS61176532A (ja) 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
KR1019860000415A KR940000540B1 (ko) 1985-01-30 1986-01-23 플라스미노겐 활성화제 전구체의 안정화 방법
ES551324A ES8802582A1 (es) 1985-01-30 1986-01-28 Un metodo para estabilizar un precursor de activador de plasminogeno.
CA000500493A CA1283047C (en) 1985-01-30 1986-01-28 Stabilized plasminogen activator precursor and method of producing the same
EP86300596A EP0190041A3 (en) 1985-01-30 1986-01-29 Stabilized plasminogen activator precursor and method of producing the same
US07/512,511 US5075230A (en) 1985-01-30 1990-04-20 Stabilized plasminogen activator precursor and method of producing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60017077A JPS61176532A (ja) 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法

Publications (2)

Publication Number Publication Date
JPS61176532A true JPS61176532A (ja) 1986-08-08
JPH0479326B2 JPH0479326B2 (enExample) 1992-12-15

Family

ID=11933913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60017077A Granted JPS61176532A (ja) 1985-01-30 1985-01-30 プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法

Country Status (6)

Country Link
US (1) US5075230A (enExample)
EP (1) EP0190041A3 (enExample)
JP (1) JPS61176532A (enExample)
KR (1) KR940000540B1 (enExample)
CA (1) CA1283047C (enExample)
ES (1) ES8802582A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤
JPH0610139B2 (ja) * 1986-05-15 1994-02-09 エモリ ユニバーシティ 繊維素溶解性合成物混合物及び血管内の血餅溶解用薬剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR940003056B1 (ko) * 1985-04-16 1994-04-13 가부시끼가이샤 미도리 쥬우지 우로키나제 전구체를 안정화시키는 방법
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
CA2091544A1 (en) * 1992-03-26 1993-09-27 Shing F. Kwan Stabilization of functional proteins
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) * 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668607A (en) * 1979-11-07 1981-06-09 Teikoku Hormone Mfg Co Ltd Medical preparation with storage stability
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5137343B2 (enExample) * 1972-12-07 1976-10-15
US4245051A (en) * 1978-03-30 1981-01-13 Rockefeller University Human serum plasminogen activator
NL7812336A (nl) * 1978-12-20 1980-06-24 Methanol Chemie Nederland Bereiding van spaanplaat.
JPS5896026A (ja) * 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
JPS58170354A (ja) * 1982-03-30 1983-10-06 Hitachi Ltd リニヤ・アクチユエ−タ
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0139447B1 (en) * 1983-09-13 1992-12-30 The Green Cross Corporation A process for preparing urokinase zymogen
DE3582338D1 (de) * 1984-01-30 1991-05-08 Asahi Chemical Ind Verfahren zur herstellung eines doppelkettigen plasminogenaktivators.
KR940003056B1 (ko) * 1985-04-16 1994-04-13 가부시끼가이샤 미도리 쥬우지 우로키나제 전구체를 안정화시키는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668607A (en) * 1979-11-07 1981-06-09 Teikoku Hormone Mfg Co Ltd Medical preparation with storage stability
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0610139B2 (ja) * 1986-05-15 1994-02-09 エモリ ユニバーシティ 繊維素溶解性合成物混合物及び血管内の血餅溶解用薬剤
JPS62292729A (ja) * 1986-06-12 1987-12-19 Toyobo Co Ltd ヒト子宮組織由来プラスミノ−ゲン活性化因子製剤

Also Published As

Publication number Publication date
KR940000540B1 (ko) 1994-01-24
EP0190041A3 (en) 1988-09-28
EP0190041A2 (en) 1986-08-06
CA1283047C (en) 1991-04-16
ES551324A0 (es) 1988-08-16
JPH0479326B2 (enExample) 1992-12-15
US5075230A (en) 1991-12-24
KR860005884A (ko) 1986-08-13
ES8802582A1 (es) 1988-08-16

Similar Documents

Publication Publication Date Title
EP0155387B1 (en) Fibronolytically active hybrid protein, process for its preparation and pharmaceutical composition
Morita et al. Derivatives of blood coagulation factor IX contain a high affinity Ca2+-binding site that lacks gamma-carboxyglutamic acid.
CN102115737B (zh) 稳定碱性磷酸酶或其标记物的试剂和方法
JP2739050B2 (ja) 抗血液凝固剤
AU607083B2 (en) Process for the activation of genetically engineered, heterologous, disulphide bridge-containing eukaryotic proteins after expression in prokaryotes
Salem et al. Human coagulation factor Va is a cofactor for the activation of protein C.
EP0100982A2 (en) Novel purified plasminogen activator, process for its production and thrombolytic composition containing it
AOKI Preparation of Plasminogen Activator from Vascular Trees of Human Cadavers Its Comparison with Urokinase
US4082612A (en) Plasminogen activator complex
JP2002249441A (ja) 血液凝固第ｖｉｉ因子を活性化するプロテアーゼ又はそのプロ酵素の安定化された液体製剤
KR940000540B1 (ko) 플라스미노겐 활성화제 전구체의 안정화 방법
EP0151308A2 (en) Urokinase complex adsorbable by fibrin and process for preparing same
Henderson et al. The Mechanism of Enhanced Streptokinase‐Induced Clot Lysis following In‐vitro Factor‐XIII Inactivation
EP0216891A1 (en) SOLVABLE FIBRINE-BASED COMPOSITION AND THEIR USE.
Kalogerakos et al. Proteolytic cleavage of methionyl transfer ribonucleic acid synthetase from Bacillus stearothermophilus: effects on activity and structure
JPH07126184A (ja) プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
US4999194A (en) Two-chain urokinase plasminogen activators for treatment of thrombotic disease
FI98123C (fi) Menetelmä ihmisen kudosplasminogeeniaktivaattorin valmistamiseksi
JPS6360938A (ja) 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
Lundblad et al. The acceleration by polylysine of the activation of factor X by factor IXa
JPS63119675A (ja) 変形組織プラスミン活性化剤
RU2247777C2 (ru) Модифицированный активатор плазминогена урокиназного типа, последовательность днк, рекомбинантная плазмида, штамм-продуцент, способ получения модифицированного активатора плазминогена урокиназного типа и фармацевтическая композиция, обладающая тромболитическим действием
EP0151996A2 (en) Process for the Preparation of a double-chain plasminogen activator
JPS60248621A (ja) 一本鎖組織プラスミノ−ゲンアクチベ−タ−の安定化方法
Warwick et al. Folate-dependent enzymes. V. Role of tryptophan in dihydrofolate reductase